Sep 16 2013
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that has signed a collaboration agreement with the Malvern Consulting Group as clinical and regulatory advisor.
"We are particularly pleased about this positive development for Relmada as the combination of our deep expertise in the pain therapeutic space with the experience of Malvern in the regulatory and clinical development process is highly synergistic and sets a solid foundation for the success of our programs" said Sergio Traversa, CEO of Relmada Therapeutics. Relmada expects to file a company IND for d-methadone in the fourth quarter of this year and start a pivotal Phase II in diabetic painful neuropathy in 2014 with timing depending on the FDA feedback.
Genes and age reveal new insights into cognitive variability, study finds